Advertisement

Characterization of Dopamine D-1 and D-2 Receptors

  • John Hyttel
  • Jørn Arnt
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)

Abstract

DA receptors can be classified into two types, D-1 and D-2 (Kebabian and Calne, 1979). The D-1 receptors are coupled to a DA-dependent adenylate cyclase (AC) in a stimulatory manner, whereas D-2 receptors are independent of AC or coupled in an inhibitory manner (Stoof and Kebabian, 1982).

Keywords

Dopamine Receptor Adenylate Cyclase Receptor Number Corpus Striatum Olfactory Tubercle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen, P.H. and Grønvald, F.C. 1985, A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum, Acta Neurol. Scand., 72:225.Google Scholar
  2. Andersen, P.H., Grønvald, F.C. and Aas Jansen, J., 1985, A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum, Life Sci., 37:1971.PubMedCrossRefGoogle Scholar
  3. Andersen, P.H. and Grønvald, F.C, 1986, Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo, Life Sci., in press.Google Scholar
  4. Amt, J., Christensen, A.V. and Hyttel, J., 1981, Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential, Neuropharmacology, 20:1331.Google Scholar
  5. Arnt, J. and Hyttel, J., 1985, Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology, 85:346.PubMedCrossRefGoogle Scholar
  6. Arnt, J., 1985 a, Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions, Life Sci., 37:717.Google Scholar
  7. Arnt, J., 1985 b, Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats, Eur. J. Pharmacol., 113:79.PubMedCrossRefGoogle Scholar
  8. Billard, W., Ruperto, V., Crosby, G., Iorio, L.C. and Barnett, A., 1984, Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum, Life Sci., 35:1885.PubMedCrossRefGoogle Scholar
  9. Burt, D.R., Creese, I. and S.H. Snyder, 1977, Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain, Science, 196:326.PubMedCrossRefGoogle Scholar
  10. Christensen, A.V., Arnt, J. and Svendsen, O., 1985, Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration, in: Dyskinesia — Research & Treatment, Casey, D., Chase, T.N., Christensen, A.V. and Gerlach, J., eds., Springer Verlag, Heidelberg.Google Scholar
  11. Christensen, A.V., Arnt, J., Hyttel, J., Larsen, J.-J. and Svendsen, O., 1984, Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics, Life Sci., 34:1529.PubMedCrossRefGoogle Scholar
  12. Christensen, A.V., Arnt, J. and Scheel-Krüger, J., 1979, Decreased antistereotypic effect of neuroleptics after additional treatment with a benzodiazepine, a GABA agonist and an anticholinergic compound. Life Sci., 24: 1395.PubMedCrossRefGoogle Scholar
  13. Christensen, A.V., Arnt, J. and Scheel-Krüger, J., 1980, GABA-dopamine/neu-roleptic interaction after systemic administration, Brain Res. Bull., 5, suppl.2:885.CrossRefGoogle Scholar
  14. Christensen, A.V. and Hyttel, J., 1981, Prolonged treatment with the GABA agonist THIP increases dopamine receptor binding more than it changes dopaminergic behaviour in mice, Drug Develop. Res., 1:255.CrossRefGoogle Scholar
  15. Christensen, A.V. and Hyttel, J., 1982, Neuroleptics and the clinical implications of adaptation of dopamine neurons, Pharmacy International, 3:329.Google Scholar
  16. Clement-Cormier, Y.C., Kebabian, J.W., Petzold, G.L. and Greengard, P., 1974, Dopamine-sensitive adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs, Proc. Nat. Acad. Sci. U.S.A., 71:1113.CrossRefGoogle Scholar
  17. Costall, B., Kelly, M.E. and Naylor, R.J., 1983, Does contralateral circling involve action of drugs on hyposensive striatal dopamine receptors in the hemisphere contralateral to denervation?, Neuropharmacology, 22:295.PubMedCrossRefGoogle Scholar
  18. Creese, I., Burt, D.R. and Snyder, S.H., 1976, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs, Science, 192:481.PubMedCrossRefGoogle Scholar
  19. Cross, A.J., Crow, T.J. and Owen, F., 1981, 3H-flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in D 2 receptors, Psychopharmacology, 74:122.PubMedCrossRefGoogle Scholar
  20. Cross, A.J., Marshal, R.D., Johnson, J.A. and Owen, F., 1983, Preferential inhibition of ligand binding to calf striatal dopamine D-1 receptors by SCH 23390, Neuropharmacology, 22:1327.PubMedCrossRefGoogle Scholar
  21. Cross, A.J. and Owen, F., 1980, Characteristics of 3H-cis-flupenthixol binding to calf brain membranes, Eur. J. Pharmacol., 65:341.PubMedCrossRefGoogle Scholar
  22. Cross, A.J. and Rossor, M., 1983, Dopamine D-1 and D-2 receptors in Huntington’s disease, Eur. J. Pharmacol., 88:223.PubMedCrossRefGoogle Scholar
  23. Cross, A.J. and Waddington, J.L., 1981, Kainic acid lesions dissociate (3H)spiperone and (3H)cis-flupenthixol binding sites in rat striatum, Eur. J. Pharmacol., 71:327.PubMedCrossRefGoogle Scholar
  24. Crow, T.J., Cross, A.J., Johnstone, E.C., Owen, F., Owens, D.G.C. and Waddington, J.L., 1981, Tardive dyskinesia — Disease process or drug effect? in: Biological Psychiatry, C. Perris, G. Stuwe and B. Jansson, eds., Elsevier/North-Holland Biomedical Press.Google Scholar
  25. Crow, T.J., Cross, A.J., Johnstone, E.C., Owen, F., Owens, D.G.C. and Waddington, J.L., 1982, Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol., 2:336.PubMedCrossRefGoogle Scholar
  26. Davies, S.W., Templeton, W.W. and Woodruff, G.N., 1982, Reduction of specific (3H)cis-flupenthixol binding sites in rat striatum following decortication, Br. J. Pharmacol., 77:358P.Google Scholar
  27. Fleminger, S., Hall, M.D., Jenner, P., Kilpatrick, G., Mann, S., Marsdem, C.D. and Rupniak, N.M.J., 1984, Differential effects of administration of haloperidol, sulpiride or clozapine for 12 months on rat striatal function, Br. J. Pharmacol., 82:288P.Google Scholar
  28. Fleminger, S., Jenner, P., Marsden, C.D. and Rupniak, N.M.J., 1982, Dopamine receptor supersensitivity produced by repeated neuroleptic administration correlates with increased D-2 receptors, Br. J. Pharmacol., 77:456P.Google Scholar
  29. Fleminger, S., Rupniak, N.M.J., Hall, M.D., Jenner, P. and Marsden, C.D., 1983, Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors, Biochem. Pharmacol., 19:2921.CrossRefGoogle Scholar
  30. Gredal, O., Nielsen, M. and Hyttel, J., 1986, Target size of dopamine D-1 receptors in rat corpus striatum estimated by 3H-SCH 23390 binding. Eur. J. Pharmacol., submitted.Google Scholar
  31. Herrera-Marschitz, M., and Ungerstedt, U., 1985, Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats, Eur. J. Pharmacol., 109:349.PubMedCrossRefGoogle Scholar
  32. Hyttel, J., 1978 a, Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)- flupenthixol binding and on adenylate cyclase activity in vitro, Life Sci., 23:551.PubMedCrossRefGoogle Scholar
  33. Hyttel, J., 1978 b, A comparison of the effect of neuroleptic drugs on the binding of 3H-haloperidol and 3H-cis(Z)-flupenthixol and on adenylate cyclase activity in rat striatal tissue in vitro, Prog. Neuro-Psychopharmacol., 2:329.CrossRefGoogle Scholar
  34. Hyttel, J., 1980, Further evidence that 3H-cis(Z)-flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum, Psychopharmacology, 67:107.PubMedCrossRefGoogle Scholar
  35. Hyttel, J., 1981, Similarities between the binding of 3H-piflutixol and 3H-flupentixol to rat striatal dopamine receptors in vitro, Life Sci., 28:563.PubMedCrossRefGoogle Scholar
  36. Hyttel, J., 1982, Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxanthene neuroleptics, in: Advances in dopamine research, M. Kohsaka, T. Shomori, Y. Tsukada and G.N. Woodruff, eds., Advances in the biosciences, 37:147. Pergamon Press, Oxford.Google Scholar
  37. Hyttel, J., 1983, SCH 23390 — The first selective dopamine D-1 antagonist, Eur. J. Pharmacol., 91:153.PubMedCrossRefGoogle Scholar
  38. Hyttel, J., 1984, Functional evidence for selective dopamine D-1 receptor blockade by SCH 23390, Neuropharmacology, 23:1395.PubMedCrossRefGoogle Scholar
  39. Hyttel, J., 1985, Dopamine D-1 and D-2 receptors. Characterization and differential effects of neuroleptics, Proceedings of the VIIIth International Symposium on Medicinal Chemistry, Dahlbom, R. and Nilsson, J.L.G., eds., Acta Pharmaceutica Suecica, suppl. 1:426.Google Scholar
  40. Hyttel, J., 1986, Effect of prolonged treatment with neuroleptics on dopamine D-1 and D-2 receptor number in corpus striatum of rat and mouse, J. Neural. Transmission, in press.Google Scholar
  41. Hyttel, J. and Arnt, J., 1986, Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions, J. Neural. Transmission, in press.Google Scholar
  42. Hyttel, J. and Christensen, A.V., 1983, Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors, J.Neu-ral.Transmiss., supp. 18:157.Google Scholar
  43. Hyttel, J. and Christensen, A.V., 1984, Do dopamine D-1 receptors contribute to the antipsychotic effects and side effects of neuroleptic drugs ?. Clin. Neuro-pharmacol. 7, suppl. 1:546.Google Scholar
  44. Hyttel, J., Christensen, A.V. and Arnt, J., 1983, Neuroleptic classification: Implications for tardive dyskinesia, Mod.Probl. Pharmacopsychiat., 21:49.Google Scholar
  45. Iorio, L.C., Barnett, A., Leitz, F.H., Houser, V.P. and Korduba, C.A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J.Pharmacol. exp. Ther., 226:462.PubMedGoogle Scholar
  46. Jenner, P., Elliott, P.N.C, Clow, A., Reavill, C and Marsden, C.D., 1978, A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs, J. Pharm. Pharmacol., 30:46.PubMedCrossRefGoogle Scholar
  47. Jenner, P., Kilpatrick, G.J. and Marsden, C.D., 1984, CHAPS solubilises D2 but not D1-binding sites from rat striatal preparations, Br. J. Pharmacol., 81:52P.Google Scholar
  48. Kebabian, J.W. and Calne, D.B., 1979, Multiple receptors for dopamine, Nature, 277:93.PubMedCrossRefGoogle Scholar
  49. Laduron, P., 1976, Limiting factors in the antagonism of neuroleptics on dopamine-sensitive adenylate cyclase, J.Pharm. Pharmacol., 28:250.PubMedCrossRefGoogle Scholar
  50. Laduron, P.M. and Leysen, J.E., 1979, Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity, Biochem. Pharmacol., 28:2161.PubMedCrossRefGoogle Scholar
  51. Leff, S., Lynne, A., Hyttel, J. and Creese, I., 1981, Kainate lesion dissociates striatal dopamine receptor radioligand binding sites, Eur. J. Pharmacol., 70:71.PubMedCrossRefGoogle Scholar
  52. Lerner, M.H., Rosengarten, H. and Friedhoff, A.J., 1981, Solubilization and characterization of 3H-spiroperidol binding sites of calf caudate, Life Sci., 29:2367.PubMedCrossRefGoogle Scholar
  53. Leysen, J.E., 1984, Receptors for neuroleptic drugs, Advances in Human Psychopharmacology, 3:315.Google Scholar
  54. Leysen, J.E., Gommeren, W. and Laduron, P.M., 1978, Spiperone: A ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding, Biochem.Pharmacol., 27:307.PubMedCrossRefGoogle Scholar
  55. Lilly, L., Frazer, C.M., Jung, C.Y., Seeman, P. and Venter, J.C., 1983, Molecular size of the canine and human brain D2 dopamine receptor as determined by radiation inactivation, Mol. Pharmacol., 24:10.PubMedGoogle Scholar
  56. Miller, R.J., Horn, A.S. and Iversen, L.L., 1974, The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3’,5’-monophosphate production in rat neostriatum and limbic forebrain, Mol.Pharmacol., 10:759.Google Scholar
  57. Murrin, L.C, 1983, Characteristics of 3H-cis-flupenthixol binding in rat striatum, Life Sci., 33:2179.PubMedCrossRefGoogle Scholar
  58. Murugaiah, K., Fleminger, J., Theodorou, A., Jenner, P., Marsden, C.D., 1983, Persistant increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake, Biochem. Pharmacol., 32:2495.PubMedCrossRefGoogle Scholar
  59. Nielsen, M., Klimek, V. and Hyttel, J., 1984, Distinct target size of dopamine D-1 and D-2 receptors in rat striatum, Life Sci., 35:325.PubMedCrossRefGoogle Scholar
  60. O’Boyle, K.M. and Waddington, J.L., 1984, Selective and stereospecific interactions of R-SK & F 38393 with (3H)piflutixol but not (3H)spiperone binding to striatal D1 and D2 dopamine receptors: Comparison with SCH 23390, Eur.J.Pharmacol., 98:433.PubMedCrossRefGoogle Scholar
  61. O’Boyle, K.M. and Waddington, J.L., 1984, Loss of rat striatal dopamine receptors with agening is selective for D-2 but not D-1 sites: Association with increased non-specific binding of the D-1 ligand (3H) piflutixol. Eur. J. Pharmacol., 105:171.PubMedCrossRefGoogle Scholar
  62. Owen, F., Cross, A.J., Crow, T.J., Poulter, M. & Waddington, J.L., 1981, Increased dopamine receptors in schizophrenia: Specificity and relationship to drugs and symptomtology, in: Biological psychiatry. C. Perris, G. Stuwe and B. Jansson, eds., Elsevier/North-Holland Biomedical Press.Google Scholar
  63. Owen, F., Cross, A.J., Waddington, J.L., Poulter, M., Gamble, S.J. and Crow T.J., 1980, Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration, Life Sci., 26:55.PubMedCrossRefGoogle Scholar
  64. Pimoule, C., Schoemaker, H., Reynolds, G.P. and Langer, S.Z., 1985, (3H) SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and parkinson’s disease, Eur. J. Pharmacol., 114:235.PubMedCrossRefGoogle Scholar
  65. Porceddu, M.L., Ongini, E. and Biggio, G., 1985, (3H) SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur. J. Pharmacol., 118:367.PubMedCrossRefGoogle Scholar
  66. Portaleone, P., Crispino, A. and DiCarlo, R., 1978, Effect of substituted benzamides on the cAMP system in the hypothalamus and striatum of the rat, Neurosci. lett., 9:233.PubMedCrossRefGoogle Scholar
  67. Raisman, R., Cash, R., Ruberg, M. Javoy-Agid, F. and Agid, Y., 1985, Binding of (3H) SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects, Eur. J. Pharmacol., 113:467.PubMedCrossRefGoogle Scholar
  68. Schultz, D.W., Stanford, E.J., Wyrick, S.W. and Mailman, R.B., 1985, Binding of (3H) SCH 23390 in rat brain: Regional distribution and effects of assay conditions and GTP suggest interaction of a D1-like dopamine receptor. J. Neurochem., 45:1601.CrossRefGoogle Scholar
  69. Schwarcz, R., Creese, I., Coyie, J.T. and Snyder, S.H., 1978, Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum, Nature, 271:766.PubMedCrossRefGoogle Scholar
  70. Seeman, P., 1980, Brain dopamine receptors, Pharmacol.Rev., 32:229.PubMedGoogle Scholar
  71. Snyder, S.H., Creese, I. and Burt, D.R., 1975, The brain’s dopamine receptor: Labelling with (3H) dopamine and (3H) haloperidol, Psychopharmacol. Commun., 1: 663.PubMedGoogle Scholar
  72. Stoof, J.C. and Kebabian, J.W., 1982, Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+- stimulated release of acetylcholine from rat neostriatum, Brain Res., 250:263.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • John Hyttel
    • 1
  • Jørn Arnt
    • 1
  1. 1.Department of Pharmacology and ToxicologyH. Lundbeck A/SCopenhagen-ValbyDenmark

Personalised recommendations